Tag - eGFR decline

  • Home
  • Tag -
  • eGFR decline

ISN Journal Editorial Selections on eGFR Decline and ADPKD Patient Perspectives

Kidney International® A Randomized, Open-label Clinical Trial Examined the Effects of Canagliflozin on Albuminuria and eGFR Decline Using An Individual Pre-Intervention eGFR Slope The CANPIONE study showed that canagliflozin significantly reduced albuminuria by 30.8% and slowed eGFR decline in patients with type 2 diabetes and microalbuminuria. Using a novel design comparing eGFR slopes before and during treatment,...

November 26, 2024Journals, News, ResearchRead more...

Jonathan Barratt and Richard Lafayette on Evolving Treatments in IgAN: Listen to the Podcast!

Join Jonathan Barratt (UK) and Richard Lafayette (US) as they explore the challenges of treating patients with IgA nephropathy (IgAN), especially younger individuals. Listen here With new medications now available, navigating treatment options has become more complex. Professor Lafayette presents a compelling case study from his practice, highlighting the real-world challenges of managing IgAN. This podcast is...

September 2, 2024Education, NewsRead more...

Sparsentan Decreased Proteinuria, but Failed to Slow eGFR Decline in FSGS: Data From the DUPLEX Trial – New Selection of Global Trials Out Now!

ISN-ACT Global Trials Focus Subgroup member Anastasiia Zykova summarizes the design and outcomes of the team's latest "Trial of the Month." Stay updated on the latest research and developments in kidney care: Access the new selection of global trials from the ISN-ACT initiative here. The "Trial of the Month" is available in several languages. Sparsentan Versus Irbesartan...

February 19, 2024News, ResearchRead more...